106 related articles for article (PubMed ID: 9326199)
21. A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Prébet T; Ducastelle S; Debotton S; Stamatoullas A; Deconinck E; Fruchart C; Gratecos N; Ifrah N; Dreyfus F; Fenaux P; Wattel E;
Hematol J; 2004; 5(3):209-15. PubMed ID: 15167906
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
23. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
24. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
De Witte T; Muus P; De Pauw B; Haanen C
Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
26. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
[TBL] [Abstract][Full Text] [Related]
27. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
28. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Br J Haematol; 2001 Jan; 112(1):118-26. PubMed ID: 11167792
[TBL] [Abstract][Full Text] [Related]
29. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Veil A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Tilly H; Brice P; Lioure B; Desablens B; Pignon B; Abgrall JP; Leporrier M; Fenaux P
Adv Exp Med Biol; 1999; 457():35-46. PubMed ID: 10500778
[TBL] [Abstract][Full Text] [Related]
30. Long-term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors.
Wattel E; Hecquet B; Grahek D; Hebbar M; Morel P; Lai JL; Bauters F; Fenaux P
Leuk Res; 1993 Sep; 17(9):733-9. PubMed ID: 8371573
[TBL] [Abstract][Full Text] [Related]
31. Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
Pogliani EM; Baldicchi L; Pioltelli P; Miccolis IR; Mangiagalli M; Corneo GM
Leuk Lymphoma; 1995 Nov; 19(5-6):473-7. PubMed ID: 8590849
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
33. Anti-Leukemia Chemotherapy of High-Risk Myelodysplastic Syndromes.
Tohyama K; Tsutani H; Wano Y; Iwasaki H; Fukushima T; Urasaki Y; Kawai Y; Nakamura T; Yoshida Y; Ueda T
Oncologist; 1997; 2(3):160-163. PubMed ID: 10388046
[TBL] [Abstract][Full Text] [Related]
34. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
35. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
36. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
37. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.
Scott BL; Storer B; Loken MR; Storb R; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2005 Jan; 11(1):65-73. PubMed ID: 15625546
[TBL] [Abstract][Full Text] [Related]
38. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
39. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Mahé B; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Buzyn A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Stamatoulas A; Tilly H; Brice P; Maloisel F; Lioure B; Desablens B; Fenaux P
Br J Haematol; 1998 Sep; 102(4):1015-24. PubMed ID: 9734653
[TBL] [Abstract][Full Text] [Related]
40. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Bernasconi C; Alessandrino EP; Bernasconi P; Bonfichi M; Lazzarino M; Canevari A; Castelli G; Brusamolino E; Pagnucco G; Castagnola C
Br J Haematol; 1998 Aug; 102(3):678-83. PubMed ID: 9722293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
